Overview

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults

Status:
Not yet recruiting
Trial end date:
2027-09-22
Target enrollment:
Participant gender:
Summary
To learn if the study drug, ulixertinib, can cross over the blood-brain barrier in patients with recurrent brain tumors
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
BioMed Valley Discoveries, Inc